Objective: To identify the prevalence and predictors of prescribing potentially inappropriate medications (PIMs) in a nationwide cohort of community dwellers with dementia requiring complex care needs. 
daily episodes of disturbing behaviours, like wandering or being abusive. 6 The interRAI was developed by an international collaboration of experts and shows good interrater reliability. The interRAI assessors who conduct the assessments are trained in a quality assurance programme conducted by the Ministry of Health, NZ. A national competency framework supports and promotes the quality assurance programmes for the interRAI assessments. 7 The interRAI-HC tool gathers information on physical, mental, social, and cognitive domains of the health of residents/clients living in home care settings. 7 Beers have defined potentially inappropriate medications (PIMs)
as the prescription of medications where risks outweigh clinical benefits, particularly when there is a safer or more effective alternative therapy for the same condition. 8 A study conducted in rural community-dwelling older adults in the United States, utilizing the Beers criteria, found that half of the population of older adults utilized over-the-counter and prescribed inappropriate medications. 9 Prescribing medications for older adults with dementia is challenging because of the risks associated with cognitive decline, behavioural and psychological disturbances, prescription of multiple medications, and their associated costs. 10, 11 Older adults with dementia also experience a greater sensitivity to the adverse effects of medications acting on the central nervous system. 12, 13 Long-term utilization of medications in older individuals with impaired physical and cognitive function has been associated with increased risks of hospitalization and mortality. 14 The 2015 Beers Criteria is often used as a tool for assessing the appropriateness of prescribing medications in the geriatric population. 15 A systematic review among older adults with cognitive impairment and dementia reported a varied prevalence of prescription of PIMs of 10.2% to 56.4% across Europe, Australia, and the United States;
and the Beers criteria were applied for assessing PIMs in majority of the studies. 16 Another recent literature review reported that among the five studies conducted in ambulatory home-dwelling patients diagnosed with dementia that used the Beers criteria, the prevalence of PIMs use ranged from 16.2% to 33%, and PIMs were found to be associated with gender, ethnicity, number of medications prescribed, and varied medical conditions. 17 An understanding about the prevalence and determinants of PIMs can help prevent adverse effects and improve the quality of prescribing in this vulnerable age group. To our knowledge, this is the first study conducted to evaluate the predictors of prescribing PIMs in older adults with dementia, receiving comprehensive geriatric risk assessments. These assessments capture a suite of sociodemographic and clinical variables that have not been previously investigated. The study aims to identify the prevalence and associations of prescribing PIMs in a nationwide cohort of community dwellers with dementia. The overarching objective of the study is to identify the factors associated with inappropriate prescribing in older adults diagnosed with dementia, identified by the 2015 version of the Beers criteria by multinomial regression, utilizing the 2015 interRAI dataset.
| MATERIALS AND METHODS
The Human Ethics Committee, University of Otago, NZ has approved the proceedings of the study (ethical approval number 15/CEN/45/AM02).
| Data source
The international Resident Assessment Instrument-Home Care (9.1) (interRAI-HC) dataset is a comprehensive geriatric risk assessment for community-dwelling older adults with complex care needs, needing publicly funded long-term community services or aged residential care in NZ. 18 In NZ, a standardized interRAI-HC has been implemented for conducting all community care assessments in older adults requiring publically funded long-term community services or aged residential care. 19 Assessors in District Health Boards throughout NZ utilize this standardised interRAI-HC assessment to assist in defining the level of support required for the geriatric population. 18 Older adults are referred by a health practitioner to have their health requirements assessed by the trained interRAI-HC assessors. Assessors visit the individuals at their residence to develop individualized treatment plans according to a standardized protocol. 20 Once the participating individuals consent to the deidentified interRAI-HC data being used for planning and research purposes, the information is then collated into the electronic interRAI-HC database, maintained by NZ's Technical Advisory Services (TAS) to provide facts and figures at the provider regional and national level. 20 The interRAI-HC assessments provide information on 20 domains, including social demographics, medical ailments, frailty, cognitive, and physical function. 19 The interRAI data- The information on all the prescription claims funded by the Pharmaceutical Management Agency (PHARMAC) was sourced from the Pharms extract files 2015, prepared by community pharmacists, and includes the sociodemographics and medication details of the individuals. 21 The cross-matched 2015 interRAI-Pharms dataset was utilized for the present study. 
Key points

| Diagnosis of dementia
Dementia was diagnosed by the Minimum Data Set (MDS) Cognitive
Performance Scale (CPS). 23 The CPS is a valid and reliable seven-point hierarchical scale derived from the MDS that rates impairment from intact memory to very severe memory loss. 24 The CPS collates data on comatose status, short-term memory, cognitive skills for daily decision making, being understood by others, and self-performance in eating; with scores ranging from 0 (intact memory) to 6 (very severe memory impairment). The CPS has been shown to be highly correlated with the Mini-Mental State Examination in a number of validation studies.
| Covariates
The individuals were grouped according to age: 65-74 years, 75-84 years, 85-94 years, and 95 years and above. Based on the literature review of known predictors of inappropriate prescribing in older adults with and without dementia, explanatory variables that were tested for their influence on prescribing patterns were as follows: 
| Statistical analysis
The potential impact of different explanatory variables on the outcome variable (PIMs) was analysed using logistic regression models.
Individuals with a diagnosis of dementia were flagged as a binary variable; those with the diseased condition were coded as 1, and the coding for no dementia was 0. 
| RESULTS
The current analysis is based on data collected from 16 568 HC assessments from 1 January 2015 to 31 December 2015, who have received at least one prescription medication funded by PHARMAC.
Our observations suggest that the female population comprised 60.1% (9964). The mean (SD) age of the population was 82.35 (7.6) years. Individuals of all ethnicities were included in the study. NZ Europeans and Māori were studied particularly, as they represent the largest ethnicities in NZ. 26 13.2% (2190) of the study population was diagnosed with dementia. Dementia was marginally more prevalent in males (14.6%) compared with females (P = 0.001), and among the Māori ethnicity (16.6%).
The sociodemographic characteristics of the study population and factors associated with prescribing of PIMs, after adjustment for confounders in individuals diagnosed with dementia, are depicted in Table 2 . Overall, we observed that 66.9% (1465/2190) of the older adults diagnosed with dementia were prescribed PIMs, of which 
| Sociodemographic predictors
Individuals more than 85 years of age were less likely to be prescribed 
| Clinical factors associated with PIMs
Older adults who were prescribed a greater number of medications were more likely to be prescribed PIMs (aOR = 1.15, CI, 1.14-1. 
| DISCUSSION
We reported the prevalence of prescription of PIMS and identified the sociodemographic and clinical variables associated with the prescription of PIMs among community-dwelling older adults with dementia.
Several studies investigating PIMs in older individuals have been carried out in NZ that made use of the Beers criteria, and have focused on community-dwelling or hospitalized older adults. 26, 30, 35 This study appears to be the first to apply the 2015 Beers criteria to examine the associations of inappropriate prescribing exclusively in community-dwelling older individuals with dementia in NZ, who have received a comprehensive geriatric risk assessment.
The NZ interRAI annual report 6 in 2016 to 2017 noted a 1.2 times higher prevalence of dementia in males, compared with females, findings consistent with those in our study. Likewise, in the present study, male individuals diagnosed with dementia were more prone to be prescribed PIMs, compared with females, which is similar to the findings of a recent study in Finland 36 that reported the male gender as a risk factor for initiation of PIMs in community-dwelling older adults with Alzheimer's disease; and the research conducted in Korea, which analysed the trends in prescribing of atypical antipsychotics in geriatric patients with dementia. 37 Numerous studies have reported a higher rate of inappropriate medication use in older women than in men of the same age-group, [38] [39] [40] although the clinical relevance of this association remains uncertain. 41 Our study observed a high prevalence of dementia in the Māori group, comparable with that observed in a study conducted in NZ to assess an indigenous approach for the diagnosis and management of dementia, 42 and to the findings of the NZ interRAI 6 annual report 2016 to 2017. It has been observed that the Māori population more than the age of 50 have worse health outcomes and a greater burden of chronic ailments than nonMāori of the same age group. 43 The prev- Alzheimer's disease. 36 These findings could potentially be attributed to prescribe awareness concerning the prescription of PIMs in individuals of the older age group. 45 There was a high prevalence of PIMs (66.9%) in older adults diagnosed with dementia in our study, comparable to the prevalence (62%) in a study conducted in community-dwelling older adults in the United
States. 46 This is a significant finding of our study. Similarly, researchers 49 PIMs with anticholinergic properties may also inhibit the potential benefits of cholinesterase inhibitors, which is the main pharmacological class, currently approved for the management of Alzheimer's disease. 53 Several researchers have attested that anticholinergics may be associated with an increased risk for the development of sustained cognitive deficits, which can range from mild cognitive impairment to dementia.
54-56
The results of the logistic regression analysis showed that the likelihood of PIMs increased with the number of medications prescribed, which is akin to the findings of the research in older people with dementia in care homes in the United Kingdom. 41 The study by Wucherer et al in community-dwelling primary care patients screened positive for dementia, 57 and the research conducted in Sweden used the EU(7)-PIM list to evaluate the prevalence of PIMs in older people with cognitive impairment. 52 A study performed in the United Kingdom, utilizing the primary care database of anonymised electronic health records from general practice, witnessed that patients more than 65 years of age diagnosed with dementia, and taking multiple medications, were more likely to be prescribed antipsychotics. 58 In our study, individuals who reported poor self-health had an increased likelihood of developing PIMs, identical to the results of a study conducted in the United States to assess potentially inappropriate anticholinergic medication use in home-dwelling older adults with dementia. 45 The Bronx Aging Study 59 revealed that patients with poor or fair ratings of self-perceived health utilized more prescription medications. Scores on self-perceived health status may be an appropriate measure of the syndrome. This is supported by the conclusion that subjects reporting fair and poor ratings on self-perceived health have increased numbers of physician visits. 59 Contrary to the analysis of studies conducted in individuals diagnosed with dementia in Sweden 60 and in eight European countries, 61 a striking result to emerge from our data is that the PIMs prevalence was higher in individuals who were functionally independent with respect to Activities of Daily Living (ADL).
The study found increased use of anticholinergic medicines in dementia. Several studies have shown that prescription of anticholinergic medicines can adversely impact cognition, physical function, and can also increase the risk of mortality. Future research will aim at utilizing the interRAI assessments for reducing anticholinergic medicines, and whether this leads to improved cognitive outcomes.
Further research will be undertaken to develop safer alternatives to anticholinergic medications in this vulnerable group.
| Strength of the study
The strength of this study includes the use of a national comprehen- 
| Limitations
The prevalence and associations of PIMs, with respect to the individ- can be developed using this information. The study design is crosssectional, hence, only the associations of prescribing PIMs have been highlighted and the causality cannot be established.
| Conclusion
In the present study, we observed that the majority of the individuals diagnosed with dementia were prescribed PIMs, indicating that the quality of prescribing needs to be improved. 32 Furthermore, important sociodemographic predictors like the male gender, European ethnicity, and relatively younger aged individuals; and clinical predictors like the prescription of anticholinergic medications, a higher number of medications prescribed, poor self-health, and functionally independent individuals, were identified as risk factors for prescribing PIMs in older adults diagnosed with dementia. Reviewing the modifiable predictors of prescribing PIMs could significantly reduce the prevalence of inappropriate prescribing in this vulnerable population.
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